PT - JOURNAL ARTICLE AU - Tanja Schjødt Jørgensen AU - Marie Skougaard AU - Rebekka Lund Hansen AU - Christine Ballegaard AU - Philip Mease AU - Vibeke Strand AU - Lene Dreyer AU - Lars Erik Kristensen TI - Relation between fatigue and ACR response in patients with psoriatic arthritis treated with TNFi therapy: a population-based cohort study AID - 10.3899/jrheum.191107 DP - 2020 Nov 15 TA - The Journal of Rheumatology PG - jrheum.191107 4099 - http://www.jrheum.org/content/early/2020/11/10/jrheum.191107.short 4100 - http://www.jrheum.org/content/early/2020/11/10/jrheum.191107.full AB - Objective The objective of this population-based cohort study was to investigate the association of fatigue with disease activity and drug survival in PsA patients receiving their first tumor necrosis factor inhibitor (TNFi). Methods Data on patient characteristics, disease activity and drug survival were obtained from the DANBIO database on all PsA patients in the period 2006 through 2015. Information on comorbidities was obtained through linkage with the Danish National Patient Registry. Results A total of 880 patients were eligible for analyses. Patients with upper median fatigue scores had statistically significant higher disease activity measure (DAS28CRP), pain and health assessment questionnaire (HAQ) scores, tender joint count, comorbidities (Charlson Comorbidity Index ≥2) and current smoking status at baseline compared to patients with lower median fatigue scores (p<0.05). In the upper median fatigue group, less patients achieved ACR responses and improvements in VAS fatigue compared to patients in the lower median fatigue group. Kaplan-Meier curves showed shorter drug survival in patients in the upper median fatigue group compared with the lower median fatigue group at 6-month followup. Conclusion Fatigue remains a dominating symptom after TNFi treatment, and is associated with higher baseline disease activity, pain and HAQ scores, more comorbidities, and increased risk of TNFi treatment discontinuation in a cohort of Danish patients with PsA. The agreement between ACR and VAS fatigue responses is weak to moderate suggesting heterogeneity between experienced fatigue and joint inflammation.